[1] Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D 18F-dopa-PET study[J]. Brain, 1999, 122(Pt 9):1637-1650.
[2] Hwang WJ, Yao WJ, Wey SP, et al. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease[J]. J Nucl Med, 2004, 45(2):207-213.
[3] Schreckenberger M, Hagele S, Siessmeier T, et al. The dopamine D2 receptor ligand 18F-desmethoxflallypride:an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism[J]. Eur J Nucl Med Mol Imaging, 2004, 31(8):1128-1135.
[4] Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopainduced dopamine release in Parkinson disease:a PET study[J]. Neurology, 2006, 67(9):1612-1617.
[5] 左传涛,林祥通,李殿友,等.晚期帕金森病患者脑内18F-FDG摄取变化及其异常脑内环路机制的探讨[J].中华核医学杂志,2004,24(2):107-109.
[6] Feigin A, Kaplitt MG, Tang C, et al. Modulation of metabolic brain networks aftcr subthalamic gene therapy for Parkinson's disease[J]. Proc Nad Acad Sci USA, 2007, 104(49):19559-19564.
[7] Henry TR, Van Heertum RL, et al. Positron emission tomography and single photon emisssion computed tomography in epilepsy care[J]. Semin Nucl Med, 2003, 33(2):88-104.
[8] Fedi M, Berkovic SF, Marini C, et al. A GABAA receptor mutation causing generalized epilepsy reduces benzodiazepine receptor binding[J]. Neuroing, 2006, 32(3):995-1000.
[9] Bouvard S, Costes N, Bonnefoi F, et al. Seizure-related short-term plasticity of benzodiazeplne receptors in partial epilepsy:a 11C-flumazenil-PET study[J]. Brain, 2005, 128(Pt6):1330-1343.
[10] Umeoka S, Matsuda K, Baba K, et al. Usefulness of 123I-iomazenil single-photon emission computed tomography in discriminating between mesial and lateral temporal lobe epilepsy in patients in whom magnetic resonance imaging demonstrates normal findings[J]. Neurosurg, 2007, 107(2):352-363.
[11] Goerres GW, Revesz T, Duncan J, et al. Imaging cerebral vasculitis in refractory epilepsy using 11C (R)-PK11195 positron emission tomography[J]. Am J Roentgenol, 2001, 176(4):1016-1018.
[12] Drayer B, Jaszczak R, Coleman E, et al. Muscarinic cholinergic receptor binding:In vivo depiction using single photon emission computed tomography and radioiodinated quinuclidinyl benzilate[J]. J Comput Assist Tomogr, 1982, 6(3):536-543.
[13] Herholz K, Weisenbach S, Zündorf G, et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease[J]. Neuroimage, 2004, 21(1):136-143.
[14] Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of alterations in aeetyleholinesterase in Alzheimer's disease. Neurosci Lett, 2005, 380(1-2):127-132.
[15] Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B[J]. Ann Neurol, 2004, 55(3):306-319.
[16] Mintun MA, Larossa GN, Sheline YI,et al. 11C-PIB in a nondemented population:potential antecedent marker of Alzheimer disease[J]. Neurology, 2006, 67(3):446-452.
[17] Yoshita M, Taki J, Yokoyama K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD[J]. Neurology, 2006, 66(12):1850-1854.
[18] Hanyu H, Shimizu S, Hirao K, et al. Comparative value of brain perfusion SPECT and 123I-MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease[J]. Eur J Nucl Med Mol Imaging, 2006, 33(3):248-253.
[19] Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence[J]. J Neurosci, 2001, (23):9414-9418.
[20] Volkow ND, Fowler JS, Gatley SJ, et al. PET evaluation of the dopamine system of the human brain[J]. J Nucl Med, 1996, 37(7):1242-1256.
[21] Chon Y H, Huang WS, Su TP, et al. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence:A SPECT study[J]. Eur Neuropsychopharmacol, 2007, 17(1):46-52.
[22] Potkin SG, Alva G, Fleming K, et al. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography[J]. Am J Psychiatry, 2002, 159(2):227-237.
[23] Parsey RV, Hastings RS, Oquendo MA. et al. Lower semtonin transporter binding potential in the human brain during major depressive episodes[J]. Am J Psychiatry, 2006, 163(1):52-58.
[24] Yasuno F, Suhara T, Okubo Y, et al. Abnormal effective connectivity of dopamine D2 receptor binding in schizophrenia[J]. Psychiatry Res, 2005, 138(3):197-207.
[25] Feng CM, Narayana S, Lancaster JL, et al. CBF changes during brain activation:fMRI vs. PET. Neuroimage, 2004, 22(1):443-446.
[26] Laureys S, Owen AM, Schiff ND. Brain function in coma, vegetative state, and related disorders. Lancet Neurol, 2004, 3(9):537-546.
[27] 张向宇,高硕,赵建国,等.不同穴位组合对脑梗死患者脑葡萄糖代谢的影响——PET研究[J].中国针灸,2007,27(1):26-30.
[28] Palmedo H, Urbach H, Bender H, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma:correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging, 2006, 33(2):164-168.